
(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
---|---|---|---|---|---|---|---|
4qvp | BO2 | Bortezomib (DB00188) | Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies. | PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6 (Saccharomyces cerevisiae) | Proteasome | ||
4r67 | 3BV | Carfilzomib (DB08889) | Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma. | PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens) | NA | ||
5d0s | 3BV | Carfilzomib (DB08889) | Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma. | PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6 (Saccharomyces cerevisiae (strain atcc 204508 / s288c)) | Proteasome | ||
5l5e | 3BV | Carfilzomib (DB08889) | Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma. | PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5 (Saccharomyces cerevisiae (strain atcc 204508 / s288c);homo sapiens;saccharomyces cerevisiae) | Proteasome | ||
5l5f | BO2 | Bortezomib (DB00188) | Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies. | PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5 (Saccharomyces cerevisiae (strain atcc 204508 / s288c);homo sapiens;saccharomyces cerevisiae) | Proteasome | ||
5l5y | 3BV | Carfilzomib (DB08889) | Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma. | PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6 (Homo sapiens;saccharomyces cerevisiae (strain atcc 204508 / s288c);saccharomyces cerevisiae) | Proteasome | ||
5l5z | BO2 | Bortezomib (DB00188) | Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies. | PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6 (Homo sapiens;saccharomyces cerevisiae (strain atcc 204508 / s288c);saccharomyces cerevisiae) | Proteasome | ||
5lf3 | BO2 | Bortezomib (DB00188) | Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies. | PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens) | Pr_beta_C | ||
5lf7 | 6V8 | Ixazomib (DB09570) | Ixazomib is a monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already. | PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens) | Pr_beta_C | ||
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |